Precision prognostics for the development of complications in diabetes

Abstract

Individuals with diabetes face higher risks for macro- and microvascular complications than their non-diabetic counterparts. The concept of precision medicine in diabetes aims to optimise treatment decisions for individual patients to reduce the risk of major diabetic complications, including cardiovascular outcomes, retinopathy, nephropathy, neuropathy and overall mortality. In this context, prognostic models can be used to estimate an individual’s risk for relevant complications based on individual risk profiles. This review aims to place the concept of prediction modelling into the context of precision prognostics. As opposed to identification of diabetes subsets, the development of prediction models, including the selection of predictors based on their longitudinal association with the outcome of interest and their discriminatory ability, allows estimation of an individual’s absolute risk of complications. As a consequence, such models provide information about potential patient subgroups and their treatment needs. This review provides insight into the methodological issues specifically related to the development and validation of prediction models for diabetes complications. We summarise existing prediction models for macro- and microvascular complications, commonly included predictors, and examples of available validation studies. The review also discusses the potential of non-classical risk markers and omics-based predictors. Finally, it gives insight into the requirements and challenges related to the clinical applications and implementation of developed predictions models to optimise medical decision making. Graphical abstract

Chemical Compounds and Ambient Factors Affecting Pancreatic Alpha-Cells Mass and Function: What Evidence?

“…However, we believe that the potential relevance is remarkable, at least considered in perspective, for the near future. Indeed, there has recently been a vigorous move towards precision medicine in diabetes, including precision diagnostics [ 116 , 117 , 118 , 119 , 120 , 121 , 122 ]. Thus, we expect that soon it may become part of the clinical routine for assessing the specific metabolic defects of a patient with diabetes, or even simple prediabetes or dysglycemia.…”

TEAD1, MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population

“…Diabetes has emerged as a pervasive global public health crisis, impacting over 0.5 billion adults worldwide. 1 It is a chronic metabolic disorder characterized by abnormally high blood glucose levels, also known as hyperglycaemia, 2 which ultimately results in the dysfunction and injuries of multiple organs, including the kidney, retina, cardiovascular system, neurons and liver. These symptoms represent the common complications of diabetes and the lack of effective therapies to date.…”

Targeting autophagy with natural products as a potential therapeutic approach for diabetic microangiopathy

“…Prolonged exposure of diabetic patients to high levels of glucose and fat in the environment triggers a sequence of lesions within the body’s microvasculature, termed diabetic microangiopathy (DMC). DMC is mainly categorized into diabetic kidney disease (DKD), diabetic retinopathy (DR), diabetic cardiomyopathy (DCM), and diabetic peripheral neuropathy (DPN) ( Schiborn and Schulze, 2022 ), and primarily affects the kidney, retina, myocardium, nerve tissue, and toes. Diabetic foot complications often manifest in the advanced stages of DPN.…”